{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:34:51Z","timestamp":1791232491816,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1598,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1111\/j.1600-0463.2011.02754.x","type":"journal-article","created":{"date-parts":[[2011,4,22]],"date-time":"2011-04-22T06:08:34Z","timestamp":1303452514000},"page":"498-504","source":"Crossref","is-referenced-by-count":13,"title":["The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis"],"prefix":"10.1111","volume":"119","author":[{"given":"MALENE","family":"RISUM","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANN","family":"MADELUNG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HENRIK","family":"BONDO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHAEL","family":"BZOREK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHAEL HOLMSGAARD","family":"KRISTENSEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"INGER MERETE","family":"STAMP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HANS CARL","family":"HASSELBALCH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,4,17]]},"reference":[{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.exphem.2009.07.005","article-title":"JAK2V617F allele burden discriminates in essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis","volume":"37","author":"Hussein","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.leukres.2008.06.002","article-title":"Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated haematological cancer Time to change our therapeutic attitude with early upfront treatment?","volume":"33","author":"Hasselbalch","year":"2009","journal-title":"Leuk Res"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1200\/JCO.2009.23.7198","article-title":"Classification of Philadelphia translocation-negative myeloproliferative neoplasms: its impact on data from clinical trials","volume":"27","author":"Naresh","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2559.2010.03545.x","article-title":"Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis","volume":"56","author":"Brousseau","year":"2010","journal-title":"Histopathology"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/j.1600-0643.2007.00807.x","article-title":"Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia","volume":"115","author":"Larsen","year":"2007","journal-title":"APMIS"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2008.20.3174","article-title":"Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy","volume":"27","author":"Campbell","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB8|cit8","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","year":"2008"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1600-0609.2007.00960.x","article-title":"The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype","volume":"79","author":"Larsen","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB10|cit10","first-page":"72","article-title":"Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers","volume":"74","author":"Hussein","year":"2007","journal-title":"Pathology"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","volume":"7","author":"Levine","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukaemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1309\/AJCPR8GINMBDG9YG","article-title":"Philadelphia chromosome-negative chronic myeloproliferative disease","volume":"132","author":"Thiele","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1002\/cncr.24440","article-title":"The 2008 World health organization classification system for myeloproliferative neoplasms: order out of chaos","volume":"115","author":"Tefferi","year":"2009","journal-title":"Cancer"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s12185-010-0529-5","article-title":"Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria","volume":"91","author":"Wadleigh","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1309\/AJCPFHUQZ9AGUEKA","article-title":"Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory","volume":"132","author":"Cankovic","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2007-01-069237","article-title":"Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617 JAK-2 mutation","volume":"110","author":"Teofili","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of the JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood-2008-03-077966","article-title":"Myeloproliferative disorders","volume":"112","author":"Levine","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.pas.0000213338.25111.d3","article-title":"Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlated with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation","volume":"31","author":"Aboudola","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.exphem.2007.07.004","article-title":"JAK2V617F-negative ET patients do not display constitutively active JAK\/STAT signalling","volume":"35","author":"Schwemmers","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1111\/j.1600-0463.2011.02754.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/asheducation-2005.1.201","article-title":"Management of polycythemia vera and essential thrombocythemia","author":"Campbell","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["APMIS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0463.2011.02754.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0463.2011.02754.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T21:54:20Z","timestamp":1625522060000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0463.2011.02754.x"}},"subtitle":["JAK2V617F ALLELE BURDEN AND STAT3- AND STAT5 PHOSPHORYLATION"],"short-title":[],"issued":{"date-parts":[[2011,4,17]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0463.2011.02754.x","relation":{},"ISSN":["0903-4641"],"issn-type":[{"value":"0903-4641","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4,17]]}}}